A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Phase of Trial: Phase III
Latest Information Update: 15 Jul 2017
At a glance
- Drugs Apixaban (Primary) ; Dalteparin sodium
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 26 Jan 2017 Planned End Date changed from 1 Dec 2020 to 1 Nov 2018.
- 26 Jan 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2018.
- 04 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.